New Horizons in the Treatment and Management of Type 2 Diabetes:

Individualizing Therapy with Novel Options

for Improved Patient Outcomes

New Horizons in the Treatment and Management of Type 2 Diabetes is a 4-part series that will
provide attendees with the latest information in Type 2 Diabetes Management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 4 or in order.

These are archives of live webinars held between February 15, 2017 and March 29, 2017.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

This series is supported by an educational grant from Lilly USA, LLC

 Description:  The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap.

Upon completion of these activities, it is anticipated that learners will be better able to identify the potential consequences of inadequate control of T2DM, apply objective disease-activity measures to determine whether patients are meeting treat-to-target goals, develop management plans for treating to target and advancing of novel therapies to achieve continued control of T2DM, and evaluate the role of the medical director, pharmacy director and nurse case manager in improving outcomes and costs in a population of T2DM patients.

Improving Glycemic Control and Cardiovascular Risk with Novel Therapies
  • Apply newly released clinical data and guidelines on combination therapies to practice regarding glycemic management in patients with T2DM
  • Examine the evidence for the use of combination regimens that include novel hyperglycemic therapies to improve glycemic control and other cardiovascular risk factors in patients with T2DM
  • Implement tailored treatment regimens for type 2 diabetes patients featuring the various additions of combination regimens over the past few years
  • Discuss recommendations for risk factor modification and adding/intensifying combination therapy in appropriate patients
Physician, Nursing and CMCN credits valid to March 30, 2019

GLP-1 Agonists, Insulin and SGLT-2 Inhibitors in the Changing Treatment Paradigm: What are the Benefits, Risks and Outcomes in Patients with Type 2 Diabetes?

  • Review the latest clinical data on GLP-1 agonists, insulins and SGLT2 inhibitors
  • Recognize the most effective place in the T2DM treatment continuum for GLP-1 agonists, newer insulins and SGLT-2 inhibitors
  • Identify patients that would best be suited for a GLP-1 agonist therapy
  • Analyze the current role of insulins in the battle against type 2 diabetes in a changing treatment paradigm
  • Examine efficacy and safety results of the EMPA-REG Outcome trial and the potential benefits and risks of SGLT-2 inhibitors in people with T2DM, with or without cardiovascular disease
  • Review barriers to treatment of newer therapies in T2DM and strategies to overcome those barriers
Physician, Nursing and CMCN credits valid to March 30, 2019

What Managed Care Needs to Now About Novel Therapies in the Evolving Management of Type 2 Diabetes

  • Discuss methods to enable optimal cost management of novel therapies to be realized by multiple T2DM stakeholders including managed care organizations
  • Analyze strategies used by managed care organizations to facilitate high quality care for members with T2DM, and how newer therapies affect those strategies
  • Discuss how newer therapies have affected managed care professionals in the T2DM arena
  • Role of medical directors and payers in type 2 diabetes management
Physician, Nursing and CMCN credits valid to March 30, 2019